Literature DB >> 28859917

Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma.

Kota Arima1, Yo-Ichi Yamashita1, Daisuke Hashimoto1, Shigeki Nakagawa1, Naoki Umezaki1, Takanobu Yamao1, Masayo Tsukamoto1, Yuki Kitano1, Kensuke Yamamura1, Tatsunori Miyata1, Hirohisa Okabe1, Takatsugu Ishimoto1, Katsunori Imai1, Akira Chikamoto1, Hideo Baba2.   

Abstract

BACKGROUND: Patients' prognoses have been predicted by the preoperative inflammation-based score, but predicting a patient's risk for operative load remains challenging. This study investigates the usefulness of the postoperative C-reactive protein/albumin (CRP/Alb) ratio in patients with pancreatic ductal adenocarcinoma (PDAC).
METHODS: This study retrospectively assessed 142 patients who underwent pancreatic resection for PDAC between 2004 and 2014. The time at which perioperative CRP/Alb ratio most influences the prognosis was identified, and the correlations among the perioperative CRP/Alb ratio, clinicopathological factors, and patient outcomes were investigated.
RESULTS: Among the perioperative CRP/Alb ratios, only a high CRP/Alb ratio at postoperative day 14 (POD14) was significantly associated with shorter overall survival (OS) and relapse-free survival (RFS). High CRP/Alb ratio at POD 14 was related to high BMI, large amount of intraoperative bleeding, and the presence of complications. Finally, high CRP/Alb at POD14 was an independent prognostic factor of poor OS and RFS.
CONCLUSIONS: The CRP/Alb ratio at POD14 is a useful predictive marker of surgical invasion, biological reaction, and prognosis in PDAC patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRP/Albumin ratio; Pancreatic ductal adenocarcinoma; Postoperative marker

Mesh:

Substances:

Year:  2017        PMID: 28859917     DOI: 10.1016/j.amjsurg.2017.08.016

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.

Authors:  Yi Lu; Chujun Li; Honglei Chen; Weijie Zhong
Journal:  Mol Biol Rep       Date:  2018-09-01       Impact factor: 2.316

2.  C-reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma.

Authors:  T Matsumoto; S Itoh; T Yoshizumi; T Kurihara; S Yoshiya; Y Mano; K Takeishi; N Harada; T Ikegami; Y Soejima; H Baba; M Mori
Journal:  BJS Open       Date:  2020-09-21

3.  Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.

Authors:  Masaaki Murakawa; Naoto Yamamoto; Yuto Kamioka; Mariko Kamiya; Satoshi Kobayashi; Makoto Ueno; Manabu Morimoto; Yosuke Atsumi; Toru Aoyama; Hiroshi Tamagawa; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

4.  C-Reactive Protein to Albumin Ratio Predicts 30-Day and 1-Year Mortality in Postoperative Patients after Admission to the Intensive Care Unit.

Authors:  Tak Kyu Oh; Eunjeong Ji; Hyo-Seok Na; Byunghun Min; Young-Tae Jeon; Sang-Hwan Do; In-Ae Song; Hee-Pyoung Park; Jung-Won Hwang
Journal:  J Clin Med       Date:  2018-02-26       Impact factor: 4.241

5.  Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis.

Authors:  Qinfen Xie; Lidong Wang; Shusen Zheng
Journal:  Dose Response       Date:  2020-06-29       Impact factor: 2.658

6.  C-reactive protein/albumin ratio is a prognostic indicator in Asians with pancreatic cancers: A meta-analysis.

Authors:  Yan-Jun Fu; Ke-Zhi Li; Ji-Hong Bai; Zhi-Qing Liang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.

Authors:  Jie Liu; Bingbing Ye; Danyan Su; Suyuan Qin; Weiying Zhao; Yusheng Pang
Journal:  Clin Rheumatol       Date:  2022-09-21       Impact factor: 3.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.